Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients — Drug still likely to benefit higher-risk patients, experts pointed out
Disclosures
The study was funded by Pfizer.
Hammond is an employee of Pfizer and reported holding stock options in Pfizer. Co-authors are employees of Pfizer or reported other ties to industry.
Gandhi and Hirsch reported no disclosures.
Primary Source
New England Journal of Medicine
Source Reference: opens in a new tab or window Hammond J, et al "Nirmatrelvir for vaccinated or unvaccinated adult outpatients with COVID-19" New Engl J Med 2024; DOI: 10.1056/NEJMoa2309003.
Secondary Source
New England Journal of Medicine
Source Reference: opens in a new tab or window Gandhi RT, Hirsch M "Treating acute COVID-19 -- final chapters still unwritten" New Engl J Med 2024; DOI: 10.1056/NEJMe2402224.